TriaGen Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

TriaGen Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66M	Buy	+15,754	New	+$2.34M	0.66%	32

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

TriaGen Wealth Management's NBIX Position: Q2 2026 in Review

TriaGen Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 15,754 shares worth $2.66M. The stake represents 0.66% of the portfolio and ranks #32 among its holdings.

270 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

TriaGen Wealth Management held 15,754 shares of Neurocrine Biosciences worth $2.66M as of Q2 2026.
Neurocrine Biosciences was a new TriaGen Wealth Management position in Q2 2026.
Neurocrine Biosciences made up 0.66% of TriaGen Wealth Management's portfolio in Q2 2026, its #32 holding.
270 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on TriaGen Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.